Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Thejew on Jun 22, 2019 12:19pm
141 Views
Post# 29852562

Patent

PatentPatent will most likely be approved, but will take a minimum of 6 months or more for approval. Really it's all about the next results for GVHD. Unless we get some other great news we  might hang around this price for the next few months and then a climb up in PPS with people anticipating good results. 

The cool thing is, based on such stellar interim results so far, final results are almost guaranteed to be excellent. I could see this running 500% or more on great results because 1) it means they have a great chance of passing Phase3 and getting full FDA approval and actually going to market for a condition with almost no current drug treatment and 2) validates the science for other disorders, such as the new pain drug. 

That combination could put us back into the .20s or even .30s (based on new share count, would have been way higher without all the dilution). 

And it also puts us in a very good situation of landing a major partnership and/or buyout from a large pharma......and I think that's what most of us are here for (: 

Go Kaly! Hold tough guys! 
Bullboard Posts